Bianca Weinstock-Guttman

List of Publications by Year
in descending order

483 papers	27,346 citations	5876 81 h-index	9311 143 g-index
485 all docs	485 docs citations	485 times ranked	15540 citing authors

#	Article	IF	Citations
1	The role of dietary antioxidant index and index of nutritional quality in MS onset: finding from an Iranian population-based incident caseâ€“control study. Nutritional Neuroscience, 2022, 25, 379-386.	1.5	14
2	Staging and stratifying cognitive dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 463-471.	1.4	17
3	Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Multiple Sclerosis Journal, 2022, 28, 790-800.	1.4	13
4	Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 487-491.	1.4	5
5	Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions. International Journal of MS Care, 2022, 24, 184-188.	0.4	7
6	Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. Multiple Sclerosis Journal, 2022, 28, 1101-1111.	1.4	23
7	Functional network dynamics and decreased conscientiousness in multiple sclerosis. Journal of Neurology, 2022, 269, 2696-2706.	1.8	9
8	Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Multiple Sclerosis and Related Disorders, 2022, 57, 103406.	0.9	9
9	Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Multiple Sclerosis and Related Disorders, 2022, 57, 103433.	0.9	26
10	Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2022, 58, 103482.	0.9	11
11	Geneâ€“environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution. Multiple Sclerosis Journal, 2022, 28, 1330-1339.	1.4	8
12	Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis. Brain Imaging and Behavior, 2022, 16, 1252-1259.	1.1	3
13	Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis. European Radiology, 2022, , 1.	2.3	1
14	Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs, 2022, 36, 45-59.	2.7	21
15	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. Neurology, 2022, 98, .	1.5	12
16	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. Vaccines, 2022, 10, 695.	2.1	16
17	A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210991.	0.5	0
18	Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients. European Journal of Neurology, 2022, , .	1.7	1

#	Article	IF	Citations
19	Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103906.	0.9	1
20	Recovery of cognitive function after relapse in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 71-78.	1.4	38
21	Diagnosis of depression in multiple sclerosis is predicted by frontalâ€“parietal white matter tract disruption. Journal of Neurology, 2021, 268, 169-177.	1.8	10
22	Conscientiousness and deterioration in employment status in multiple sclerosis over 3â€‰years. Multiple Sclerosis Journal, 2021, 27, 1125-1135.	1.4	11
23	Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Crossâ€Sectional Structural <scp>MRI</scp> Study. Journal of Magnetic Resonance Imaging, 2021, 53, 731-739.	1.9	19
24	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102653.	0.9	13
25	Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. Multiple Sclerosis Journal, 2021, 27, 1077-1087.	1.4	18
26	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 48.	4.5	11
27	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 2021, 32, 102802.	1.4	5
28	Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. NeuroImage: Clinical, 2021, 29, 102554.	1.4	3
29	Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. NeuroImage: Clinical, 2021, 31, 102705.	1.4	3
30	Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. Journal of Neurology, 2021, 268, 2578-2588.	1.8	18
31	Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Review of Neurotherapeutics, 2021, 21, 353-364.	1.4	11
32	Three-Day Dietary Manipulation in Multiple Sclerosis. International Journal of MS Care, 2021, 23, 199-205.	0.4	2
33	Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. Journal of Neurology, 2021, 268, 4796-4808.	1.8	3
34	The cholesterol autoxidation products, 7-ketocholesterol and 7Î²-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102864.	0.9	3
35	Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. Journal of Neuroimaging, 2021, 31, 995-1002.	1.0	3
36	Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient. Multiple Sclerosis Journal, 2021, 27, 2291-2292.	1.4	8

#	Article	IF	Citations
37	Preliminary Support of a Behavioral Intervention for Trait Conscientiousness in Multiple Sclerosis. International Journal of MS Care, 2021, 24, 45-53.	0.4	3
38	Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs, 2021, 35, 743-767.	2.7	30
39	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	4
40	Gut microbiome is associated with multiple sclerosis activity in children. Annals of Clinical and Translational Neurology, 2021, 8, 1867-1883.	1.7	21
41	Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis. Journal of the Neurological Sciences, 2021, 427, 117552.	0.3	10
42	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. Neurodegenerative Disease Management, 2021, 11, 329-340.	1.2	4
43	Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient. Acta Neurologica Belgica, 2021, , 1.	0.5	2
44	Peripheral nervous system electrodiagnostic abnormalities in predominantly Hispanic Multiple Sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 56, 103254.	0.9	1
45	Manifestations and impact of the COVIDâ€19 pandemic in neuroinflammatory diseases. Annals of Clinical and Translational Neurology, 2021, 8, 918-928.	1.7	21
46	Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron <scp>MRI</scp>. Human Brain Mapping, 2021, 42, 1463-1474.	1.9	27
47	Impact of Cognitive Impairment and Dysarthria on Spoken Language in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2021, 27, 450-460.	1.2	4
48	Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 109-113.	1.4	10
49	Dalfampridine benefits ambulation but not cognition in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 91-98.	1.4	15
50	Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium. Multiple Sclerosis Journal, 2020, 26, 99-108.	1.4	27
51	Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 245-252.	1.4	12
52	Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. Multiple Sclerosis Journal, 2020, 26, 201-209.	1.4	24
53	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. Multiple Sclerosis Journal, 2020, 26, 322-332.	1.4	28
54	Vitamin D genes influence MS relapses in children. Multiple Sclerosis Journal, 2020, 26, 894-901.	1.4	17

#	Article	IF	Citations
55	Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1433-1436.	1.4	8
56	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Multiple Sclerosis Journal, 2020, 26, 1670-1681.	1.4	61
57	Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of followâ€up. European Journal of Neurology, 2020, 27, 188.	1.7	26
58	Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis. European Journal of Neurology, 2020, 27, 235-243.	1.7	9
59	Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. Journal of Vascular Research, 2020, 57, 16-23.	0.6	7
60	Multiple sclerosis in 2019: predicting progression. Lancet Neurology, The, 2020, 19, 12-14.	4.9	1
61	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Multiple Sclerosis Journal, 2020, 26, 1938-1947.	1.4	18
62	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. Journal of Neurology, 2020, 267, 802-811.	1.8	11
63	Late onset multiple sclerosis is associated with more severe ventricle expansion. Multiple Sclerosis and Related Disorders, 2020, 46, 102588.	0.9	13
64	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	4.9	64
65	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	0.6	8
66	Longitudinal Magnetic Resonance Imaging of Cerebral Microbleeds in Multiple Sclerosis Patients. Diagnostics, 2020, 10, 942.	1.3	3
67	Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 553616.	1.1	4
68	Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opinion on Drug Safety, 2020, 19, 1121-1142.	1.0	16
69	Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology, 2020, 95, e1844-e1853.	1.5	11
70	Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. Frontiers in Neurology, 2020, 11, 700.	1.1	12
71	Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102389.	0.9	15
72	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1577-1583.	1.2	4

#	Article	IF	Citations
73	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. Diagnostics, 2020, 10, 685.	1.3	4
74	High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. Journal of the Neurological Sciences, 2020, 418, 117120.	0.3	5
75	Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain, 2020, 143, 2733-2741.	3.7	45
76	Sexâ€Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 342-350.	1.0	12
77	Functional Connectivity and Structural Disruption in the Defaultâ€Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 523-530.	1.0	21
78	Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study. Multiple Sclerosis and Related Disorders, 2020, 42, 102131.	0.9	3
79	Dietary inflammatory index and risk of multiple sclerosis: Findings from a large population-based incident caseâ€“control study. Clinical Nutrition, 2020, 39, 3402-3407.	2.3	30
80	Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinsonâ€™s disease, mild cognitive impairment, Alzheimerâ€™s disease, and elderly healthy controls. Neurobiology of Aging, 2020, 90, 84-92.	1.5	14
81	Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines, 2020, 8, 50.	2.1	37
82	Realâ€World Effectiveness of Initial Diseaseâ€Modifying Therapies in Pediatric <scp>Multiple Sclerosis</scp>. Annals of Neurology, 2020, 88, 42-55.	2.8	68
83	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 821-834.	1.4	17
84	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. Cognitive and Behavioral Neurology, 2020, 33, 294-300.	0.5	3
85	Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. Fluids and Barriers of the CNS, 2020, 17, 9.	2.4	7
86	Serum neurofilament light chain and optical coherence tomography measures in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	22
87	Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5â€year longitudinal study. European Journal of Neurology, 2019, 26, 87.	1.7	72
88	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. Clinical Autonomic Research, 2019, 29, 329-338.	1.4	6
89	Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. Multiple Sclerosis Journal, 2019, 25, 1243-1254.	1.4	33
90	Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology, 2019, 93, e611-e623.	1.5	30

#	Article	IF	Citations
91	Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. Neurodegenerative Disease Management, 2019, 9, 149-172.	1.2	41
92	Serum neurofilament light chain levels associations with gray matter pathology: a 5â€year longitudinal study. Annals of Clinical and Translational Neurology, 2019, 6, 1757-1770.	1.7	66
93	High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: AAfatigue-metabolism nexus?. Journal of Clinical Lipidology, 2019, 13, 654-663.e1.	0.6	17
94	Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 615-623.	1.0	8
95	Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. Human Brain Mapping, 2019, 40, 5231-5241.	1.9	37
96	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology, 2019, 293, 424-433.	3.6	36
97	Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101388.	0.9	22
98	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genetics, 2019, 15, e1007808.	1.5	48
99	Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study. PLoS ONE, 2019, 14, e0218075.	1.1	26
100	Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. Multiple Sclerosis and Related Disorders, 2019, 34, 103-111.	0.9	24
101	mi RNA contributions to pediatricâ€onset multiple sclerosis inferred from GWAS. Annals of Clinical and Translational Neurology, 2019, 6, 1053-1061.	1.7	10
102	Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. Journal of Lipid Research, 2019, 60, 1190-1198.	2.0	31
103	No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5â€‰years. BMC Neurology, 2019, 19, 121.	0.8	5
104	Aging and Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 527-535.	1.0	33
105	Epidemiology and treatment of multiple sclerosis in elderly populations. Nature Reviews Neurology, 2019, 15, 329-342.	4.9	185
106	Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities. Expert Review of Neurotherapeutics, 2019, 19, 445-458.	1.4	25
107	Cognitive Profiles of Aging in Multiple Sclerosis. Frontiers in Aging Neuroscience, 2019, 11, 105.	1.7	43
108	Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study. American Journal of Neuroradiology, 2019, 40, 620-625.	1.2	22

#	Article	IF	Citations
109	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. Journal of Clinical Medicine, 2019, 8, 344.	1.0	17
110	Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. Journal of Comparative Effectiveness Research, 2019, 8, 305-316.	0.6	14
111	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. Journal of Neurology, 2019, 266, 866-875.	1.8	36
112	Decrease in size of secondary neck vessels and cerebral aqueduct enlargement in multiple sclerosis: a 5-year longitudinal MRI study. Veins and Lymphatics, 2019, 8, .	0.1	0
113	Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives . Patient Related Outcome Measures, 2019, Volume 10, 373-384.	0.7	9
114	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. Journal of Child Neurology, 2019, 34, 148-152.	0.7	5
115	Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?. Thrombosis and Haemostasis, 2019, 119, 175-178.	1.8	6
116	Medical History and Multiple Sclerosis: A Population-Based Incident Case-Control Study. Neuroepidemiology, 2019, 52, 55-62.	1.1	3
117	Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. Multiple Sclerosis and Related Disorders, 2019, 27, 298-304.	0.9	16
118	Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls. NeuroImage, 2019, 186, 308-320.	2.1	25
119	Plasma levels of soluble NCAM in multiple sclerosis. Journal of the Neurological Sciences, 2019, 396, 36-41.	0.3	13
120	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Multiple Sclerosis and Related Disorders, 2019, 27, 65-73.	0.9	6
121	Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study. Current Neurovascular Research, 2019, 16, 215-223.	0.4	6
122	The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regeneration Research, 2019, 14, 373.	1.6	114
123	Impact of Nutritional Intake on Function in People with Mild-to-Moderate Multiple Sclerosis. International Journal of MS Care, 2019, 21, 1-9.	0.4	24
124	Marijuana Use by Patients with Multiple Sclerosis. International Journal of MS Care, 2019, 21, 57-62.	0.4	10
125	An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis. CNS Drugs, 2018, 32, 161-178.	2.7	19
126	Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. Journal of Alternative and Complementary Medicine, 2018, 24, 596-602.	2.1	31

#	Article	IF	Citations
127	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 22, 103-107.	0.9	2
128	No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study. Current Medical Research and Opinion, 2018, 34, 1431-1440.	0.9	6
129	Effect of switching from glatiramer acetate 20â€¯mg/daily to glatiramer acetate 40â€¯mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. Journal of the Neurological Sciences, 2018, 387, 152-156.	0.3	7
130	Longitudinal personality change associated with cognitive decline in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1909-1912.	1.4	24
131	Improved cognitive performance and event-related potential changes following working memory training in patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731774762.	0.5	23
132	Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 642-647.	1.2	38
133	Assessing â€˜No Evidence of Disease Activityâ€™ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. CNS Drugs, 2018, 32, 75-84.	2.7	31
134	Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. American Journal of Neuroradiology, 2018, 39, 289-295.	1.2	24
135	Interferon Î² for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a032003.	2.9	116
136	Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. European Journal of Neurology, 2018, 25, 584-e36.	1.7	11
137	Extracranial venous angioplasty is ineffective to treat MS. Nature Reviews Neurology, 2018, 14, 129-130.	4.9	8
138	Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. Journal of the Neurological Sciences, 2018, 388, 175-181.	0.3	15
139	Preliminary investigation of cognitive function in aged multiple sclerosis patients: Challenges in detecting comorbid Alzheimerâ€™s disease. Multiple Sclerosis and Related Disorders, 2018, 22, 52-56.	0.9	17
140	Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. NeuroImage: Clinical, 2018, 18, 1007-1016.	1.4	32
141	Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?. Multiple Sclerosis Journal, 2018, 24, 205-213.	1.4	16
142	Dietary factors and pediatric multiple sclerosis: A case-control study. Multiple Sclerosis Journal, 2018, 24, 1067-1076.	1.4	27
143	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. NeuroImage, 2018, 167, 438-452.	2.1	60
144	Genetic risk factors for pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1825-1834.	1.4	37

#	Article	IF	Citations
145	Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 123-130.	1.2	25
146	Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. NeuroImage: Clinical, 2018, 17, 530-540.	1.4	32
147	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. American Journal of Neuroradiology, 2018, 39, 2237-2242.	1.2	25
148	Heterogeneity in association of remote herpesvirus infections and pediatric <scp>MS</scp>. Annals of Clinical and Translational Neurology, 2018, 5, 1222-1228.	1.7	25
149	Stress-full life events and multiple sclerosis: A population-based incident case-control study. Multiple Sclerosis and Related Disorders, 2018, 26, 168-172.	0.9	15
150	Urban air quality and associations with pediatric multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1146-1153.	1.7	29
151	Several household chemical exposures are associated with pediatricâ€onset multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1513-1521.	1.7	8
152	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology, 2018, 91, e1778-e1787.	1.5	55
153	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 846-855.	13.9	201
154	The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsingâ€“Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. CNS Drugs, 2018, 32, 763-770.	2.7	14
155	Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 490-495.	1.0	50
156	Hemostasis biomarkers in multiple sclerosis. European Journal of Neurology, 2018, 25, 1169-1176.	1.7	25
157	Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. American Journal of Neuroradiology, 2018, 39, 1480-1486.	1.2	13
158	Separate and Combined Influence of Cognitive Impairment and Dysarthria on Functional Communication in Multiple Sclerosis. American Journal of Speech-Language Pathology, 2018, 27, 1051-1065.	0.9	34
159	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. Radiology, 2018, 289, 487-496.	3.6	75
160	A decline in cognitive function should lead to a change in disease-modifying therapy â€“ Yes. Multiple Sclerosis Journal, 2018, 24, 1681-1682.	1.4	9
161	Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2018, 25, 37-42.	0.9	11
162	White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Human Brain Mapping, 2018, 39, 3682-3690.	1.9	23

#	Article	IF	Citations
163	Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study. Acta Neurologica Scandinavica, 2018, 138, 308-314.	1.0	16
164	Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MSâ€MRIUS. Journal of Neuroimaging, 2018, 28, 399-405.	1.0	12
165	Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 1703-1709.	1.2	14
166	Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. Journal of the Neurological Sciences, 2018, 393, 128-134.	0.3	26
167	Thalamic white matter in multiple sclerosis: A combined diffusionâ€tensor imaging and quantitative susceptibility mapping study. Human Brain Mapping, 2018, 39, 4007-4017.	1.9	19
168	Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. International Journal of MS Care, 2018, 20, 9-14.	0.4	66
169	Multiple Sclerosis and Associated Comorbidities. , 2018, , .		0
170	Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population. Journal of the Neurological Sciences, 2017, 375, 371-375.	0.3	5
171	Two decades of glatiramer acetate: From initial discovery to the current development of generics. Journal of the Neurological Sciences, 2017, 376, 255-259.	0.3	40
172	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology, 2017, 88, 1623-1629.	1.5	138
173	Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis. Pediatrics, 2017, 139, e20162838.	1.0	40
174	An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practiceâ€"The MSâ€MRIUS Study. Journal of Neuroimaging, 2017, 27, 339-347.	1.0	14
175	Serum lipid profile changes predict neurodegeneration in interferon-Î²1a-treated multiple sclerosis patients. Journal of Lipid Research, 2017, 58, 403-411.	2.0	43
176	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology, 2017, 89, 1584-1593.	1.5	65
177	Examining the contributions of environmental quality to pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 164-169.	0.9	21
178	Is Multiple Sclerosis Associated With a Lower Intraocular Pressure?. Journal of Neuro-Ophthalmology, 2017, 37, 265-267.	0.4	5
179	Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opinion on Biological Therapy, 2017, 17, 1163-1172.	1.4	28
180	Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Multiple Sclerosis Journal, 2017, 23, 1336-1345.	1.4	93

#	Article	IF	Citations
181	Differential effects of aging on motor and cognitive functioning in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1385-1393.	1.4	42
182	Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 792-801.	1.4	38
183	Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis. Current Neurovascular Research, 2017, 14, 266-273.	0.4	7
184	Global and regional brain atrophy is associated with low or retrograde facial vein flow in multiple sclerosis. Veins and Lymphatics, 2017, 6, .	0.1	2
185	Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis. International Journal of MS Care, 2017, 19, 297-302.	0.4	5
186	Treatment Considerations in Female MS Patients of Reproductive Age. , 2017, , 35-48.		0
187	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310051.	0.9	95
188	Multiple Sclerosis Subtypes. , 2016, , 55-65.		0
189	Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. European Journal of Neurology, 2016, 23, 1101-1109.	1.7	18
190	Characteristics of Children and Adolescents With Multiple Sclerosis. Pediatrics, 2016, 138, .	1.0	89
191	Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study. BMC Neurology, 2016, 16, 108.	0.8	6
192	Dietary salt intake and time to relapse in paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1350-1353.	0.9	58
193	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. Annals of Clinical and Translational Neurology, 2016, 3, 897-907.	1.7	67
194	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 6, 87-92.	0.9	58
195	Benchmarks of meaningful impairment on the MSFC and BICAMS. Multiple Sclerosis Journal, 2016, 22, 1874-1882.	1.4	42
196	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 2016, 16, 777-793.	1.4	126
197	Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?. Expert Review of Neurotherapeutics, 2016, 16, 765-775.	1.4	37
198	Aging and multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 717-725.	1.4	128

#	Article	IF	Citations
199	MRI in the evaluation of pediatric multiple sclerosis. Neurology, 2016, 87, S88-96.	1.5	42
200	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. The Cochrane Library, 2016, 2016, CD009333.	1.5	46
201	Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2016, 22, 920-927.	1.2	18
202	Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. Journal of the Neurological Sciences, 2016, 370, 13-17.	0.3	23
203	Use of natalizumab in multiple sclerosis: current perspectives. Expert Opinion on Biological Therapy, 2016, 16, 1151-1162.	1.4	14
204	Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurology, 2016, 16, 102.	0.8	11
205	Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. Radiology, 2016, 281, 884-895.	3.6	63
206	Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report. Multiple Sclerosis and Related Disorders, 2016, 9, 54-55.	0.9	5
207	Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e190.	3.1	39
208	Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. Journal of Neuroimmunology, 2016, 292, 68-78.	1.1	29
209	Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis. Pediatric Neurology, 2016, 57, 64-73.	1.0	22
210	Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 937-943.	0.9	15
211	Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 1010-1016.	1.2	27
212	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. Journal of the Neurological Sciences, 2016, 363, 153-157.	0.3	137
213	Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis. CNS Drugs, 2016, 30, 209-225.	2.7	23
214	Extended interval dosing of natalizumab in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 885-889.	0.9	118
215	Clinical features of neuromyelitis optica in children. Neurology, 2016, 86, 245-252.	1.5	100
216	Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. Multiple Sclerosis Journal, 2016, 22, 1327-1336.	1.4	88

#	Article	IF	Citations
217	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Multiple Sclerosis Journal, 2016, 22, 770-781.	1.4	37
218	Stable neuropsychiatric status in multiple sclerosis: a 3-year study. Multiple Sclerosis Journal, 2016, 22, 569-574.	1.4	11
219	Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurology, 2015, 15, 232.	0.8	12
220	Simultaneous Determination of Oxysterols, Cholesterol and 25-Hydroxy-Vitamin D3 in Human Plasma by LC-UV-MS. PLoS ONE, 2015, 10, e0123771.	1.1	27
221	Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2015, 4, 228-233.	0.9	9
222	Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. BMC Neurology, 2015, 15, 135.	0.8	9
223	Immunologic and MRI markers of the therapeutic effect of IFN-Î²-1a in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e176.	3.1	13
224	Comparative efficacy of interferon Î² versus glatiramer acetate for relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1016-1020.	0.9	13
225	The US Network of Pediatric Multiple Sclerosis Centers. Journal of Child Neurology, 2015, 30, 1381-1387.	0.7	21
226	Identifying employed multiple sclerosis patients at-risk for job loss: When do negative work events pose a threat?. Multiple Sclerosis and Related Disorders, 2015, 4, 409-413.	0.9	31
227	A new perspective on proxy report: Investigating implicit processes of understanding through patientâ€“proxy congruence. Quality of Life Research, 2015, 24, 2637-2649.	1.5	10
228	Blood circulating microparticle species in relapsingâ€“remitting and secondary progressive multiple sclerosis. A caseâ€“control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. Journal of the Neurological Sciences, 2015, 355, 84-89.	0.3	22
229	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsingâ€“remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2015, 8, 59-70.	1.5	5
230	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsingâ€“remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. Journal of Neuroimmunology, 2015, 281, 44-50.	1.1	3
231	Disclosure of disease status among employed multiple sclerosis patients: Association with negative work events and accommodations. Multiple Sclerosis Journal, 2015, 21, 225-234.	1.4	34
232	Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus. American Journal of Neuroradiology, 2015, 36, 1874-1883.	1.2	33
233	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. Journal of Lipid Research, 2015, 56, 2010-2018.	2.0	45
234	Increased contrast enhancing lesion activity in relapsingâ€“remitting multiple sclerosis migraine patients. NeuroImage: Clinical, 2015, 9, 110-116.	1.4	16

#	Article	IF	Citations
235	Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Multiple Sclerosis Journal, 2015, 21, 858-865.	1.4	46
236	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Journal of Neurology, 2015, 262, 326-336.	1.8	20
237	Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. PLoS ONE, 2015, 10, e0129503.	1.1	8
238	Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. Multiple Sclerosis Journal, 2014, 20, 1502-1510.	1.4	70
239	Negative work events and accommodations in employed multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 116-119.	1.4	42
240	MS disease activity in RESTORE. Neurology, 2014, 82, 1491-1498.	1.5	166
241	Transitions between SNF and home-based care in patients with multiple sclerosis. NeuroRehabilitation, 2014, 34, 531-540.	0.5	5
242	Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology, 2014, 83, 441-449.	1.5	43
243	Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango. Expert Opinion on Biological Therapy, 2014, 14, 115-126.	1.4	12
244	Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 83, 1484-1486.	1.5	11
245	Characterizing cognitive function during relapse in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1745-1752.	1.4	92
246	Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis. Human Brain Mapping, 2014, 35, 53-60.	1.9	14
247	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Journal of Neuroimmunology, 2014, 273, 58-64.	1.1	21
248	Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis. Neurology, 2014, 82, 1083-1092.	1.5	159
249	Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. European Journal of Neurology, 2014, 21, 1137.	1.7	22
250	Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 830-836.	1.4	10
251	Protective environmental factors for neuromyelitis optica. Neurology, 2014, 83, 1923-1929.	1.5	23
252	No Regional Gray Matter Atrophy Differences between Pediatricâ€•and Adultâ€Onset Relapsingâ€Remitting Multiple Sclerosis. Journal of Neuroimaging, 2014, 24, 63-67.	1.0	3

#	Article	IF	Citations
253	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. , 2014, , CD009333.		18
254	Phase White Matter Signal Abnormalities in Patients with Clinically Isolated Syndrome and Other Neurologic Disorders. American Journal of Neuroradiology, 2014, 35, 1916-1923.	1.2	11
255	Subcortical Deep Gray Matter Pathology in Patients with Multiple Sclerosis Is Associated with White Matter Lesion Burden and Atrophy but Not with Cortical Atrophy: A Diffusion Tensor MRI Study. American Journal of Neuroradiology, 2014, 35, 912-919.	1.2	44
256	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 424-433.	1.2	14
257	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 859-864.	0.9	35
258	MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. BMC Neurology, 2014, 14, 131.	0.8	11
259	Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review. Neurology and Therapy, 2014, 3, 29-39.	1.4	11
260	Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2014, 35, 106-112.	1.2	50
261	Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. Journal of Magnetic Resonance Imaging, 2014, 40, 1215-1222.	1.9	31
262	Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions. CNS Drugs, 2014, 28, 731-742.	2.7	34
263	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. Journal of the Neurological Sciences, 2014, 338, 128-134.	0.3	20
264	Cognitive deficits in pediatric-onset multiple sclerosis: what does the future hold?. Neurodegenerative Disease Management, 2014, 4, 137-146.	1.2	8
265	Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsingâ€“Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study. PLoS ONE, 2014, 9, e91098.	1.1	17
266	Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	0.8	26
267	Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. Clinical Neurology and Neurosurgery, 2013, 115, S49-S54.	0.6	2
268	Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. European Journal of Neurology, 2013, 20, 1264-1271.	1.7	19
269	Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: Results of the PREMiSe pilot study. BMC Neurology, 2013, 13, 151.	0.8	15
270	The neurological disease ontology. Journal of Biomedical Semantics, 2013, 4, 42.	0.9	32

#	Article	IF	Citations
271	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurology, 2013, 13, 173.	0.8	4
272	Changes of Cine Cerebrospinal Fluid Dynamics in Patients with Multiple Sclerosis Treated with Percutaneous Transluminal Angioplasty: A Case-control Study. Journal of Vascular and Interventional Radiology, 2013, 24, 829-838.	0.2	31
273	Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers. Journal of the Neurological Sciences, 2013, 330, 71-77.	0.3	44
274	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 2013, 263, 121-127.	1.1	14
275	Comparison of Intravascular Ultrasound with Conventional Venography for Detection of Extracranial Venous Abnormalities Indicative of Chronic Cerebrospinal Venous Insufficiency. Journal of Vascular and Interventional Radiology, 2013, 24, 1487-1498.e1.	0.2	25
276	Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. Journal of Neurology, 2013, 260, 489-497.	1.8	33
277	Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1075-1081.	0.9	36
278	Speech and pause characteristics in multiple sclerosis: A preliminary study of speakers with high and low neuropsychological test performance. Clinical Linguistics and Phonetics, 2013, 27, 134-151.	0.5	44
279	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 567-576.	1.4	28
280	Influence of Personality on the Relationship Between Gray Matter Volume and Neuropsychiatric Symptoms in Multiple Sclerosis. Psychosomatic Medicine, 2013, 75, 253-261.	1.3	24
281	Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1478-1484.	1.4	85
282	MRI characteristics of familial and sporadic multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1145-1152.	1.4	10
283	Lipid profiles are associated with lesion formation over 24â€...months in interferon-Î² treated patients following the first demyelinating event. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1186-1191.	0.9	114
284	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 891-895.	1.4	32
285	Fatigue and Depression in Children With Demyelinating Disorders. Journal of Child Neurology, 2013, 28, 713-718.	0.7	61
286	Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: No. Multiple Sclerosis Journal, 2013, 19, 858-860.	1.4	7
287	Is There Extra Cost of Institutional Care for MS Patients?. Multiple Sclerosis International, 2013, 2013, 1-7.	0.4	10
288	Influence of Cognitive Function on Speech and Articulation Rate in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2013, 19, 173-180.	1.2	50

#	Article	IF	Citations
289	Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis. Journal of Child Neurology, 2013, 28, 102-107.	0.7	121
290	Active Cognitive Reserve Influences the Regional Atrophy to Cognition Link in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2013, 19, 1128-1133.	1.2	22
291	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. Frontiers in Bioscience - Elite, 2013, E5, 525-532.	0.9	24
292	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. PLoS ONE, 2013, 8, e53996.	1.1	68
293	Impact of diagnosis and early treatment on the course of multiple sclerosis. American Journal of Managed Care, 2013, 19, s321-31.	0.8	61
294	An update on new and emerging therapies for relapsing-remitting multiple sclerosis. American Journal of Managed Care, 2013, 19, s343-54.	0.8	18
295	Unemployment in multiple sclerosis: the contribution of personality and disease. Multiple Sclerosis Journal, 2012, 18, 647-653.	1.4	138
296	Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. International Journal of Molecular Sciences, 2012, 13, 5659-5673.	1.8	1
297	Advances in therapy, imaging and risk factors in MS. Nature Reviews Neurology, 2012, 8, 66-68.	4.9	9
298	Vitamin D and Multiple Sclerosis. Neurologist, 2012, 18, 179-183.	0.4	20
299	Cognitive impairment is associated with reduced bone mass in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1459-1465.	1.4	18
300	Randomized controlled trial of atorvastatin in clinically isolated syndrome. Neurology, 2012, 78, 1171-1178.	1.5	43
301	Intra- and Extraluminal Structural and Functional Venous Anomalies in Multiple Sclerosis, as Evidenced by 2 Noninvasive Imaging Techniques. American Journal of Neuroradiology, 2012, 33, 16-23.	1.2	40
302	No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1913-1917.	1.2	15
303	Regression-Based Norms Improve the Sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric Multiple Sclerosis (NBPMS). Clinical Neuropsychologist, 2012, 26, 985-1002.	1.5	28
304	Iron Deposition on SWI-Filtered Phase in the Subcortical Deep Gray Matter of Patients with Clinically Isolated Syndrome May Precede Structure-Specific Atrophy. American Journal of Neuroradiology, 2012, 33, 1596-1601.	1.2	55
305	Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. Neurological Research, 2012, 34, 819-827.	0.6	16
306	Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurological Research, 2012, 34, 761-769.	0.6	14

#	Article	IF	Citations
307	Arterial, venous and other vascular risk factors in multiple sclerosis. Neurological Research, 2012, 34, 754-760.	0.6	24
308	Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. Neurological Research, 2012, 34, 793-801.	0.6	8
309	Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNÎ²-1a in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1125-1134.	1.4	36
310	Role of Venoplasty for Treatment of Multiple Sclerosis: Value of Open-label Studies and Surrogate Treatment Outcomes. Journal of Vascular and Interventional Radiology, 2012, 23, 1308-1310.	0.2	8
311	Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC Neurology, 2012, 12, 26.	0.8	15
312	Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis. NeuroImage, 2012, 59, 331-339.	2.1	176
313	The nervous system's potential role in multiple sclerosis associated bone loss. Journal of the Neurological Sciences, 2012, 319, 8-14.	0.3	10
314	Limb ataxia originating from peri-central sulcus demyelinating lesion in multiple sclerosis. Journal of the Neurological Sciences, 2012, 320, 136-140.	0.3	6
315	The Management of Pediatric Multiple Sclerosis. Journal of Child Neurology, 2012, 27, 1384-1393.	0.7	14
316	Iron deposition in multiple sclerosis lesions measured by susceptibilityâ€weighted imaging filtered phase: A case control study. Journal of Magnetic Resonance Imaging, 2012, 36, 73-83.	1.9	60
317	Cine cerebrospinal fluid imaging in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2012, 36, 825-834.	1.9	46
318	Patterns of dietary and herbal supplement use by multiple sclerosis patients. Journal of Neurology, 2012, 259, 637-644.	1.8	29
319	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology, 2012, 259, 898-905.	1.8	66
320	Venous Angioplasty in Patients with Multiple Sclerosis: Results of a Pilot Study. European Journal of Vascular and Endovascular Surgery, 2012, 43, 116-122.	0.8	73
321	Regarding CCSVI and MS: A Never-ending Story or a New Chapter?. European Journal of Vascular and Endovascular Surgery, 2012, 43, 129-130.	0.8	3
322	Regarding CCSVI: Is Blinding the Key?. European Journal of Vascular and Endovascular Surgery, 2012, 43, 126.	0.8	0
323	Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. Journal of Neuroimmunology, 2012, 243, 61-68.	1.1	27
324	Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. Journal of Neurology, 2012, 259, 139-146.	1.8	274

#	Article	IF	Citations
325	Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients. Minerva Medica, 2012, 103, 97-102.	0.3	2
326	Vitamin D and multiple sclerosis: can vitamin D prevent disease progression?. Expert Review of Neurotherapeutics, 2011, 11, 469-471.	1.4	5
327	Upper and Lower Extremity Motor Function and Cognitive Impairment in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2011, 17, 643-653.	1.2	121
328	The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology, 2011, 18, 43-52.	1.0	23
329	Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. Pathophysiology, 2011, 18, 53-60.	1.0	24
330	Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A caseâ€“control diffusion imaging study. Pathophysiology, 2011, 18, 61-68.	1.0	11
331	Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, 86-91.	0.3	29
332	Gerstmannâ€“StrÃ¤usslerâ€“Scheinker syndrome masquerading multiple sclerosis. Journal of the Neurological Sciences, 2011, 309, 55-57.	0.3	8
333	Regression-Based Pediatric Norms for the Brief Visuospatial Memory Test â€“ Revised and the Symbol Digit Modalities Test. Clinical Neuropsychologist, 2011, 25, 402-412.	1.5	26
334	Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers. PLoS ONE, 2011, 6, e28062.	1.1	40
335	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. Journal of Neuroimmunology, 2011, 236, 76-80.	1.1	12
336	Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis. Inflammation Research, 2011, 60, 457-465.	1.6	42
337	Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. Advances in Therapy, 2011, 28, 270-278.	1.3	24
338	Iron deposition and inflammation in multiple sclerosis. Which one comes first?. BMC Neuroscience, 2011, 12, 60.	0.8	26
339	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurology, 2011, 11, 128.	0.8	50
340	Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. BMC Medicine, 2011, 9, 22.	2.3	77
341	Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. Journal of Neuroinflammation, 2011, 8, 127.	3.1	186
342	Comment on â€œno evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onsetâ€• Annals of Neurology, 2011, 69, 1062-1063.	2.8	3

#	Article	IF	Citations
343	Common viruses associated with lower pediatric multiple sclerosis risk. Neurology, 2011, 76, 1989-1995.	1.5	141
344	Use of MR Venography for Characterization of the Extracranial Venous System in Patients with Multiple Sclerosis and Healthy Control Subjects. Radiology, 2011, 258, 562-570.	3.6	81
345	Value of MR Venography for Detection of Internal Jugular Vein Anomalies in Multiple Sclerosis: A Pilot Longitudinal Study. American Journal of Neuroradiology, 2011, 32, 938-946.	1.2	63
346	Disease progression in pediatric multiple sclerosis: disparities between physical and neurocognitive outcomes. Expert Review of Neurotherapeutics, 2011, 11, 433-440.	1.4	12
347	Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 189-195.	0.9	84
348	Visual-cognitive processing deficits in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 449-456.	1.4	31
349	Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology, 2011, 76, 1500-1507.	1.5	122
350	The NEO-FFI in Multiple Sclerosis: Internal Consistency, Factorial Validity, and Correspondence Between Self and Informant Reports. Assessment, 2011, 18, 39-49.	1.9	34
351	Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Archives of Neurology, 2011, 68, 437.	4.9	101
352	Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Review of Neurotherapeutics, 2011, 11, 1277-1294.	1.4	47
353	Fingolimod for the treatment of relapsing multiple sclerosis. Expert Review of Neurotherapeutics, 2011, 11, 165-183.	1.4	29
354	Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 157-163.	1.4	16
355	Change in quality of life in patients with relapsingâ€“remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon Î²-1a. Multiple Sclerosis Journal, 2011, 17, 734-742.	1.4	21
356	Cost-effectiveness of disease-modifying therapy for multiple sclerosis. Neurology, 2011, 77, 355-363.	1.5	92
357	Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology, 2011, 77, 138-144.	1.5	189
358	Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients. PLoS ONE, 2011, 6, e16802.	1.1	14
359	Cognition and Physical Disability in Predicting Health-Related Quality of Life in Multiple Sclerosis. International Journal of MS Care, 2011, 13, 57-63.	0.4	22
360	Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. Functional Neurology, 2011, 26, 205-14.	1.3	24

#	Article	IF	Citations
361	MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. Journal of Neurology, 2010, 257, 63-71.	1.8	26
362	Multiple sclerosis: predicting risk and delaying progression. Lancet Neurology, The, 2010, 9, 7-9.	4.9	5
363	Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. Journal of Neuroimmunology, 2010, 223, 92-99.	1.1	58
364	Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Multiple Sclerosis Journal, 2010, 16, 588-596.	1.4	74
365	The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Journal of the International Neuropsychological Society, 2010, 16, 6-16.	1.2	159
366	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 15-28.	1.5	29
367	Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology, 2010, 74, 538-544.	1.5	58
368	Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2010, 67, 1329-35.	4.9	65
369	Natalizumab in pediatric multiple sclerosis patients. Therapeutic Advances in Neurological Disorders, 2010, 3, 293-299.	1.5	35
370	Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clinical Neuropsychologist, 2010, 24, 1131-1145.	1.5	205
371	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2010, 292, 28-35.	0.3	56
372	Ultrasensitive Quantification of Serum Vitamin D Metabolites Using Selective Solid-Phase Extraction Coupled to Microflow Liquid Chromatography and Isotope-Dilution Mass Spectrometry. Analytical Chemistry, 2010, 82, 2488-2497.	3.2	98
373	Cerebellar Mutism in Pediatric Acute Disseminated Encephalomyelitis. Pediatric Neurology, 2010, 42, 259-266.	1.0	30
374	Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Multiple Sclerosis Journal, 2010, 16, 228-237.	1.4	224
375	Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy, 2010, 11, 505-520.	0.9	24
376	Phytosterols (PS) as immunomodulators of Multiple Sclerosis (MS). FASEB Journal, 2010, 24, 332.8.	0.2	0
377	Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. International Angiology, 2010, 29, 127-39.	0.4	66
378	CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. International Angiology, 2010, 29, 140-8.	0.4	24

#	Article	IF	Citations
379	Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. International Angiology, 2010, 29, 158-75.	0.4	54
380	Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 201-206.	0.9	174
381	Retinal nerve fiber thickness in inflammatory demyelinating diseases of childhood onset. Multiple Sclerosis Journal, 2009, 15, 802-810.	1.4	54
382	Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Multiple Sclerosis Journal, 2009, 15, 998-1005.	1.4	91
383	Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain, 2009, 132, 3392-3400.	3.7	130
384	Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology, 2009, 73, 504-510.	1.5	116
385	Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 620-625.	0.9	58
386	Geneâ€“environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. Journal of Neuroimmunology, 2009, 209, 123-130.	1.1	35
387	Mechanisms of interferon-Î² effects on bone homeostasis. Biochemical Pharmacology, 2009, 77, 1757-1762.	2.0	37
388	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology, 2009, 256, 405-415.	1.8	193
389	Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Multiple Sclerosis Journal, 2009, 15, 345-354.	1.4	62
390	Comparison of the immunomodulatory effects of the plant sterol Î²-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. International Immunopharmacology, 2009, 9, 153-157.	1.7	51
391	Personality traits in women with multiple sclerosis: Discrepancy in patient/partner report and disease course. Journal of Psychosomatic Research, 2009, 66, 147-154.	1.2	19
392	Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Multiple Sclerosis Journal, 2009, 15, 1077-1084.	1.4	185
393	Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Current Medical Research and Opinion, 2009, 25, 2459-2470.	0.9	24
394	The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. Functional Neurology, 2009, 24, 133-8.	1.3	76
395	Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurology, The, 2008, 7, 173-183.	4.9	70
396	Genomic effects of once-weekly, intramuscular interferon-Î²1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. Journal of Neuroimmunology, 2008, 205, 113-125.	1.1	34

#	Article	IF	Citations
397	Quercetin and interferon-Î² modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. Journal of Neuroimmunology, 2008, 205, 142-147.	1.1	97
398	Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. Journal of the Neurological Sciences, 2008, 268, 12-17.	0.3	147
399	Interferon-Î² treatment for relapsing multiple sclerosis. Expert Opinion on Biological Therapy, 2008, 8, 1435-1447.	1.4	38
400	Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity. Multiple Sclerosis Journal, 2008, 14, 759-763.	1.4	43
401	Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Multiple Sclerosis Journal, 2008, 14, 1061-1067.	1.4	35
402	Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Multiple Sclerosis Journal, 2008, 14, 940-946.	1.4	163
403	Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis. American Journal of Neuroradiology, 2008, 29, 319-325.	1.2	62
404	Cortical atrophy and personality in multiple sclerosis.. Neuropsychology, 2008, 22, 432-441.	1.0	44
405	MRI features of pediatric multiple sclerosis. Neurology, 2007, 68, S46-S53.	1.5	68
406	Clinical features of children and adolescents with multiple sclerosis. Neurology, 2007, 68, S37-S45.	1.5	103
407	Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 722-730.	1.4	91
408	The incidence and significance of anti-natalizumab antibodies. Neurology, 2007, 69, 1391-1403.	1.5	312
409	Preservation of gray matter volume in multiple sclerosis patients with the MetÂallele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Human Molecular Genetics, 2007, 16, 2659-2668.	1.4	93
410	An association between autoreactive antibodies and anti-interferon-Î² antibodies in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 895-899.	1.4	12
411	Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Multiple Sclerosis Journal, 2007, 13, 52-57.	1.4	297
412	Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. NeuroImage, 2007, 36, 746-754.	2.1	45
413	Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. NeuroImage, 2007, 36, 1294-1300.	2.1	109
414	Validity of the Wisconsin Card Sorting and Delisâ€“Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 215-223.	0.8	77

#	Article	IF	Citations
415	Thalamic atrophy and cognition in multiple sclerosis. Neurology, 2007, 69, 1213-1223.	1.5	446
416	Healthâ€related quality of life in multiple sclerosis: effects of natalizumab. Annals of Neurology, 2007, 62, 335-346.	2.8	172
417	Pharmacogenetics of MXA SNPs in interferon-Î² treated multiple sclerosis patients. Journal of Neuroimmunology, 2007, 182, 236-239.	1.1	38
418	Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2007, 187, 159-165.	1.1	43
419	Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. Journal of Neuroimmunology, 2007, 188, 167-174.	1.1	57
420	New MRI criteria in the diagnosis of multiple sclerosis. Lancet Neurology, The, 2007, 6, 664-665.	4.9	6
421	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurology, The, 2007, 6, 773-781.	4.9	292
422	Interferon Inhibitory Activity in Patients With Multiple Sclerosis. Archives of Neurology, 2006, 63, 1579.	4.9	17
423	Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Journal of the International Neuropsychological Society, 2006, 12, 549-58.	1.2	633
424	Dynamics of interferon-Î² modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-Î² neutralizing antibodies. Journal of Neuroimmunology, 2006, 176, 125-133.	1.1	41
425	Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 437-444.	1.4	147
426	Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354, 911-923.	13.9	1,249
427	Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease). Archives of Neurology, 2006, 63, 957.	4.9	167
428	Neocortical Atrophy, Third Ventricular Width, and Cognitive Dysfunction in Multiple Sclerosis. Archives of Neurology, 2006, 63, 1301.	4.9	282
429	Interferon-Î² modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Multiple Sclerosis Journal, 2006, 12, 541-550.	1.4	34
430	Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology, 2006, 66, 685-692.	1.5	276
431	Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. Journal of the International Neuropsychological Society, 2005, 11, 574-83.	1.2	92
432	Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Multiple Sclerosis Journal, 2005, 11, 626-634.	1.4	55

#	Article	IF	Citations
433	A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Multiple Sclerosis Journal, 2005, 11, 573-582.	1.4	79
434	Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity. Archives of Neurology, 2005, 62, 1371.	4.9	91
435	The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction. NeuroImage, 2005, 26, 1068-1077.	2.1	161
436	Low fat dietary intervention with Ï‰-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 397-404.	1.0	183
437	Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of the Neurological Sciences, 2005, 231, 29-34.	0.3	446
438	MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. Journal of the Neurological Sciences, 2005, 234, 17-24.	0.3	99
439	Regional lobar atrophy predicts memory impairment in multiple sclerosis. American Journal of Neuroradiology, 2005, 26, 1824-31.	1.2	73
440	Prediction of Neuropsychological Impairment in Multiple Sclerosis. Archives of Neurology, 2004, 61, 226.	4.9	351
441	Reliable screening for neuropsychological impairment in multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 675-678.	1.4	234
442	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology, 2004, 63, 2039-2045.	1.5	275
443	Multiple sclerosis gender issues: clinical practices of women neurologists. Multiple Sclerosis Journal, 2004, 10, 582-588.	1.4	52
444	Combination Therapy for Multiple Sclerosis. CNS Drugs, 2004, 18, 777-792.	2.7	22
445	Functional imaging during covert auditory attention in multiple sclerosis. Journal of the Neurological Sciences, 2004, 218, 9-15.	0.3	17
446	Risk of bone loss in men with multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 170-175.	1.4	100
447	Construct Validity and Frequency of Euphoria Sclerotica in Multiple Sclerosis. Journal of Neuropsychiatry and Clinical Neurosciences, 2004, 16, 350-356.	0.9	39
448	Sensory Abnormalities in MS. International Journal of MS Care, 2004, 6, 144-147.	0.4	1
449	Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. American Journal of Neuroradiology, 2004, 25, 985-96.	1.2	40
450	Dynamics of immune cell trafficking in interferon-Î² treated multiple sclerosis patients. Journal of Neuroimmunology, 2003, 139, 84-92.	1.1	22

#	Article	IF	Citations
451	Thalamic Involvement in Multiple Sclerosis: A Diffusionâ€Weighted Magnetic Resonance Imaging Study. Journal of Neuroimaging, 2003, 13, 307-314.	1.0	84
452	Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. Journal of the Neurological Sciences, 2003, 209, 93-99.	0.3	69
453	Factors that predict Health-Related Q uality of Life in patients with relapsing -remitting multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 1-5.	1.4	61
454	Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 529-534.	1.4	70
455	Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 393-396.	1.4	281
456	Genomic Effects of IFN-Î² in Multiple Sclerosis Patients. Journal of Immunology, 2003, 171, 2694-2702.	0.4	113
457	Multiple sclerosis characteristics in A frican A merican patients in the New York State Multiple Sclerosis C onsortium. Multiple Sclerosis Journal, 2003, 9, 293-298.	1.4	113
458	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study. , 2003, 13, 307-314.		38
459	Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. , 2003, 13, 307-14.		21
460	In vivo gene expression revealed by cDNA arrays: the pattern in relapsingâ€“remitting multiple sclerosis patients compared with normal subjects. Journal of Neuroimmunology, 2001, 116, 213-219.	1.1	102
461	Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology, 2001, 56, 1324-1330.	1.5	121
462	What is New in the Treatment of Multiple Sclerosis?. Drugs, 2000, 59, 401-410.	4.9	59
463	A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Multiple Sclerosis Journal, 2000, 6, 267-273.	1.4	6
464	Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Multiple Sclerosis Journal, 2000, 6, 373-377.	1.4	19
465	Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25). Multiple Sclerosis Journal, 2000, 6, 382-385.	1.4	2
466	Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays. Drug Metabolism and Disposition, 2000, 28, 987-93.	1.7	21
467	Cerebrospinal fluid abnormalities in a phase III trial of AvonexÂ® (IFNÎ²-1a) for relapsing multiple sclerosis1Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc.1. Journal of Neuroimmunology, 1999, 93, 8-14.	1.1	95
468	Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis. International Journal of MS Care, 1999, 1, 3-11.	0.4	11

#	Article	IF	Citations
469	Magnetic resonance studies of intramuscular interferon ?-1a for relapsing multiple sclerosis. Annals of Neurology, 1998, 43, 79-87.	2.8	346
470	HLA-DP: A Class II Restriction Molecule Involved in Epitope Spreading During the Development of Multiple Sclerosis. Human Immunology, 1998, 59, 15-24.	1.2	40
471	Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology, 1998, 50, 1266-1272.	1.5	309
472	Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. Multiple Sclerosis Journal, 1998, 4, 480-486.	1.4	3
473	Devic's disease: Diagnostic and therapeutic challenge. Multiple Sclerosis Journal, 1997, 3, 408-408.	1.4	1
474	TREATMENT OF FULMINANT MULTIPLE SCLEROSIS WITH INTRAVENOUS CYCLOPHOSPHAMIDE. Neurologist, 1997, 3, 178-185.	0.4	42
475	Prescribing Recommendations For Interferon-Beta In Multiple Sclerosis. CNS Drugs, 1997, 8, 102-112.	2.7	14
476	Management of Multiple Sclerosis. New England Journal of Medicine, 1997, 337, 1604-1611.	13.9	179
477	Diversity and plasticity of self recognition during the development of multiple sclerosis.. Journal of Clinical Investigation, 1997, 99, 1682-1690.	3.9	155
478	Newer Versus Older Treatments for Relapsing-Remitting Multiple Sclerosis. Drug Safety, 1996, 14, 121-130.	1.4	5
479	Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals of Neurology, 1996, 39, 285-294.	2.8	2,365
480	Unusual Long-Standing Gd-DTPA Enhancement in a Chronic Progressive Myelopathy. Journal of Computer Assisted Tomography, 1995, 19, 649-651.	0.5	1
481	The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis. Annals of Neurology, 1995, 37, 7-15.	2.8	214
482	A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Journal, 1995, 1, 118-135.	1.4	97
483	Management of pediatric multiple sclerosis. , 0, , 632-644.		0